Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2021 08:00 ET | Source: atai Life Sciences

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
September 21, 2021 08:00 ET | Source: atai Life Sciences

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use...
September 15, 2021 08:10 ET | Source: atai Life Sciences

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
September 14, 2021 08:00 ET | Source: atai Life Sciences

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in...
September 09, 2021 16:30 ET | Source: atai Life Sciences

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
September 03, 2021 18:00 ET | Source: atai Life Sciences

atai Life Sciences to Participate in Upcoming September Investor Conferences

BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
August 17, 2021 15:57 ET | Source: Atai Life Sciences

atai Life Sciences legt Finanzergebnisse für das zweite Quartal 2021 und Unternehmens-Update vor

- Erfolgreicher Nasdaq-Börsengang mit erzieltem Bruttoerlös von 258,8 Millionen US-Dollar, einschließlich Überzuteilung des Unterzeichners - Erhalt von Vorauszahlung von Otsuka in Höhe 20 Millionen...
August 16, 2021 07:00 ET | Source: atai Life Sciences

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as...
August 12, 2021 08:50 ET | Source: atai Life Sciences

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
August 10, 2021 15:10 ET | Source: Atai Life Sciences

atai Life Sciences legt in Telefonkonferenz und Webcast die Finanzergebnisse des zweiten Quartals 2021 und ein Update zur Geschäftsentwicklung vor

BERLIN, Aug. 10, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das die Transformation der Behandlung von...